Analysis

Cardiol Therapeutics Inc. Class A (CRDL) Stock Analysis

Cardiol Therapeutics Inc. Class A investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to CRDL.

websiteCRDL/analysis/CRDL

Cardiol Therapeutics Inc. Class A

Cardiol Therapeutics Inc. Class A investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to CRDL.

Stock profile

Ticker

CRDL

Asset type

Stock

Market cap

$122.3M

Sector

Health Technology

Industry

Biotechnology

Currency

CAD

Ticker listings

Cardiol Therapeutics Inc. Class A may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • CRDL primary listing
  • A2PA9E
  • CT9

Latest Cardiol Therapeutics Inc. Class A news

Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for...

Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ

Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Inv...

Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association

Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the Ame...

Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program

Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in ...

Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart

Toronto, Ontario--(Newsfile Corp. - April 14, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (...

Research sections

Valuation

Review valuation context for Cardiol Therapeutics Inc. Class A.

Future growth

Review future growth context for Cardiol Therapeutics Inc. Class A.

Past performance

Review past performance context for Cardiol Therapeutics Inc. Class A.

Financial health

Review financial health context for Cardiol Therapeutics Inc. Class A.

Dividend

Review dividend context for Cardiol Therapeutics Inc. Class A.

Management

Review management context for Cardiol Therapeutics Inc. Class A.

Ownership

Review ownership context for Cardiol Therapeutics Inc. Class A.

Other information

Review other information context for Cardiol Therapeutics Inc. Class A.

Community

Review community context for Cardiol Therapeutics Inc. Class A.